Overview

Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia

Status:
RECRUITING
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
ICU patients with severe hyponatremia and a high risk of rapid SNa overcorrection.
Phase:
PHASE3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Treatments:
Deamino Arginine Vasopressin